Sana Biotechnology Inc (SANA) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Sana Biotechnology Inc $0.39, price $2.89, upside -86.5%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sana Biotechnology Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range $1.34 – $25.88 · fair‑value band $0.2900 – $0.5800 · the $2.89 price screens above the $0.3900 fair value. Dashed = 300-day average. As of Jul 18, 2026.
Follow Sana Biotechnology in your weekly email
Every Wednesday you see whether Sana Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Show more
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Stock analysis
Sana Biotechnology Inc (SANA) currently trades at $2.89, while our model-based Fair Value estimate is $0.3900, 86.5% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.2900 (bear) to $0.5800 (bull), the price of $2.89 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Sana Biotechnology Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$244M in FY2025.
Key figures
Market cap $935M · EPS (TTM) $−0.9200 · Return on equity −147% · Return on assets (EBIT) −43.4% · Free cash flow −$145M · Net debt $7.0M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −87%, SANA screens richer than that median.
Fair Value models
Bear $0.2900Fair Value $0.3900Bull $0.5800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside−86.5% · Bottom 25%
Profitability
Return on assets−27.5% · Below median
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B5.81× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sana Biotechnology Inc (SANA) overvalued or undervalued?
As of Jul 18, 2026, our model estimates a fair value of $0.3900 versus a price of $2.89, about −87% upside (overvalued).
What is the fair value of SANA?
Our model-based fair value for Sana Biotechnology Inc is $0.3900 (as of Jul 18, 2026), built from audited fundamentals. The current price: $2.89.
What is the quality score of SANA?
Sana Biotechnology Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sana Biotechnology Inc (SANA)?
Our model-based price target is the fair value of $0.3900 (as of Jul 18, 2026) from 1 valuation models. Cautious scenario $0.2900, optimistic scenario $0.5800. It is a calculation from audited fundamentals, not an analyst target.
What is the Sana Biotechnology Inc stock forecast for 2026?
Our models put fair value at $0.3900, about −87% upside versus a price of $2.89 (overvalued). Cautious scenario $0.2900, optimistic scenario $0.5800. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Sana Biotechnology Inc (SANA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sana Biotechnology Inc it is $0.3900 per share (as of Jul 18, 2026), against a price of $2.89. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sana Biotechnology Inc stock overvalued or undervalued in 2026?
As of Jul 18, 2026, SANA trades above its calculated fair value: price $2.89, fair value $0.3900, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SANA?
No. The price is what the market pays today ($2.89); the fair value is what the company's own numbers justify ($0.3900). For Sana Biotechnology Inc the two are $2.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sana Biotechnology Inc worth?
The market values Sana Biotechnology Inc at about $935M (market capitalisation, as of Jul 18, 2026). Per share that is $2.89; our models calculate a fair value of $0.3900 per share.
What do the bullish and bearish scenarios say about SANA?
Our models span a range for Sana Biotechnology Inc: cautious scenario $0.2900, base $0.3900, optimistic $0.5800 per share (as of Jul 18, 2026, price $2.89). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sana Biotechnology Inc (SANA)?
Balance-sheet figures for Sana Biotechnology Inc (as of Jul 18, 2026): return on equity −147.4%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is SANA from its 52-week high?
Sana Biotechnology Inc trades at $2.89, about 51% below its 52-week high of $5.92 and 8% above the low of $2.68 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3900 is for.
Which stocks are comparable to Sana Biotechnology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sana Biotechnology Inc stock attractive at the current price?
The data as of Jul 18, 2026: price $2.89, calculated fair value $0.3900 (−87%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SANA calculated?
We run Sana Biotechnology Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sana Biotechnology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sana Biotechnology Inc (SANA)?
The closing price on Oct 2, 2026 was $2.89. Our model-based fair value is $0.3900, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sana Biotechnology Inc right now?
The price sits above even our optimistic bull case ($0.5800). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2900 to $0.5800) leaves room in how you read the outcome.
Key figures of Sana Biotechnology Inc
How large is the market capitalisation of Sana Biotechnology Inc (SANA)?
The market capitalisation of Sana Biotechnology Inc is $935M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sana Biotechnology Inc (SANA)?
Earnings per share at Sana Biotechnology Inc are $−0.9200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sana Biotechnology Inc (SANA)?
The return on equity (ROE) of Sana Biotechnology Inc is −147% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sana Biotechnology Inc (SANA)?
On an EBIT basis the return on assets of Sana Biotechnology Inc is −43.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Sana Biotechnology Inc (SANA) generate?
The free cash flow of Sana Biotechnology Inc is −$145M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sana Biotechnology Inc (SANA) carry?
The net debt of Sana Biotechnology Inc is $7.0M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sana Biotechnology Inc in the live analysis
One click puts Sana Biotechnology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jul 18, 2026